Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?
| Autor: | Konrad Zuzda, Wiktoria Grycuk, Jacek Małyszko, Jolanta Małyszko |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Expert Opinion on Therapeutic Targets. 26:995-1009 |
| ISSN: | 1744-7631 1472-8222 |
| DOI: | 10.1080/14728222.2022.2161887 |
| Popis: | Altered lipid distribution and metabolism may lead to the development and/or progression of chronic kidney disease (CKD). Dyslipidemia is a major risk factor for CKD and increases the risk of cardiovascular events and mortality. Therefore, lipid-lowering treatments may decrease cardiovascular risk and prevent death.Key players involved in regulating lipid accumulation in the kidney; contribution of lipids to CKD progression, lipotoxicity, and mitochondrial dysfunction in kidney disease; recent therapeutic approaches for dyslipidemia.The precise mechanisms for regulating lipid metabolism, particularly in kidney disease, are poorly understood. Guidelines for lipid-lowering therapy for CKD are controversial. Several hypolipemic therapies are available, but compared to others, statin therapy is the most common. No clinical trial has evaluated the efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in preventing cardiovascular events or improving kidney function among patients with CKD or kidney transplant recipients. Attractive alternatives, such as PCSK9-small interfering RNA (siRNA) molecules or evinacumab are available. Additionally, several promising agents, such as cyclodextrins and the FXR/TGR5 dual agonist, INT-767, can improve renal lipid metabolism disorders and delay CKD progression. Drugs targeting mitochondrial dysfunction could be an option for the treatment of dyslipidemia and lipotoxicity, particularly in renal diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|